S'abonner

Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients - 01/08/17

Doi : 10.1016/j.ahj.2017.05.005 
Tullio Palmerini, MD a, Patrick Serruys, MD b, Arie Pieter Kappetein, MD c, Philippe Genereux, MD d, e, f, Diego Della Riva, MD a, Letizia Bacchi Reggiani, MStat a, Evald Høj Christiansen, MD g, Niels R. Holm, MD g, Leif Thuesen, DMSc h, Timo Makikallio, MD i, Marie Claude Morice, MD j, Jung-Min Ahn, MD k, Seung-Jung Park, MD k, Holger Thiele, MD l, Enno Boudriot, MD m, Mario Sabatino, MD a, Mattia Romanello, MD a, Giuseppe Biondi-Zoccai, MD n, o, Raphael Cavalcante, MD p, Joseph F. Sabik, MD q, Gregg W. Stone, MD d,
a Polo Cardio-Toraco-Vascolare, Policlinico S. Orsola, Bologna, Italy 
b International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom 
c Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands 
d Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 
e Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada 
f Morristown Medical Center, Morristown, NJ 
g Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark 
h Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark 
i Department of Cardiology, Oulu University Hospital, Oulu, Finland 
j MC Moriec Ramsay Générale de Santé, ICPS, Massy, France 
k The Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 
l University Heart Center Lübeck and the German Center for Cardiovascular Research (DZHK), Lübeck, Germany 
m Department of Internal Medicine/Cardiology, University Heart Center, Leipzig, Germany 
n Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy 
o Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy 
p Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands 
q The Cleveland Clinic Foundation, Cleveland, OH 

Reprint request: Gregg W. Stone, MD, Columbia University Medical Center, NewYork-Presbyterian Hospital, The Cardiovascular Research Foundation, 1700 Broadway 8th Floor, New York, NY 10019.Columbia University Medical Center, NewYork-Presbyterian Hospital, The Cardiovascular Research Foundation1700 Broadway 8th FloorNew YorkNY10019

Background

Some but not all randomized controlled trials (RCT) have suggested that percutaneous coronary intervention (PCI) with drug-eluting stents may be an acceptable alternative to coronary artery bypass grafting (CABG) surgery for the treatment of unprotected left main coronary artery disease (ULMCAD). We therefore aimed to compare the risk of all-cause mortality between PCI and CABG in patients with ULMCAD in a pairwise meta-analysis of RCT.

Methods

Randomized controlled trials comparing PCI vs CABG for the treatment of ULMCAD were searched through MEDLINE, EMBASE, Cochrane databases, and proceedings of international meetings.

Results

Six trials including 4,686 randomized patients were identified. After a median follow-up of 39 months, there were no significant differences between PCI vs CABG in the risk of all-cause mortality (hazard ratio [HR] 0.99, 95% CI 0.76-1.30) or cardiac mortality. However, a significant interaction for cardiac mortality (Pinteraction= .03) was apparent between randomization arm and SYNTAX score, such that the relative risk for mortality tended to be lower with PCI compared with CABG among patients in the lower SYNTAX score tertile, similar in the intermediate tertile, and higher in the upper SYNTAX score tertile. Percutaneous coronary intervention compared with CABG was associated with a similar long-term composite risk of death, myocardial infarction, or stroke (HR 1.06, 95% CI 0.82-1.37), with fewer events within 30 days after PCI offset by fewer events after 30 days with CABG (Pinteraction < .0001). Percutaneous coronary intervention was associated with greater rates of unplanned revascularization compared with CABG (HR 1.74, 95% CI 1.47-2.07).

Conclusions

In patients undergoing revascularization for ULMCAD, PCI was associated with similar rates of mortality compared with CABG at a median follow-up of 39 months, but with an interaction effect suggesting relatively lower mortality with PCI in patients with low SYNTAX score and relatively lower mortality with CABG in patients with high SYNTAX score. Both procedures resulted in similar long-term composite rates of death, myocardial infarction, or stroke, with PCI offering an early safety advantage and CABG demonstrating greater durability.

Le texte complet de cet article est disponible en PDF.

Plan


© 2017  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 190

P. 54-63 - août 2017 Retour au numéro
Article précédent Article précédent
  • Retained cardiac implantable electronic device fragments are not associated with magnetic resonance imaging safety issues, morbidity, or mortality after orthotopic heart transplant
  • Christopher O. Austin, Kevin Landolfo, Pragnesh P. Parikh, Parag C. Patel, K.L. Venkatachalam, Fred M. Kusumoto
| Article suivant Article suivant
  • Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry
  • Marco Proietti, K.E. Juhani Airaksinen, Andrea Rubboli, Axel Schlitt, Tuomas Kiviniemi, Pasi P. Karjalainen, Gregory YH Lip, on behalf of the AFCAS Study Group

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.